CCR5 and HIV infectious disease: The ex vivo system (primary hPBMCs) experiments demonstrated xfR5-D+T NP induced CCR5 blocking and intracellular ARV drug release, which provides two levels of protection against new HIV infection or latently infected HIV+ cells.